KPV

KPV is the tail end of alpha-melanocyte-stimulating hormone (α-MSH) — its C-terminal three amino acids. It appears to carry much of α-MSH's anti-inflammatory punch while largely leaving pigmentation alone. In cells and animals it quiets pro-inflammatory signaling, NF-κB in particular, inside immune and epithelial cells. It also gets pulled directly into intestinal cells, which is why the gut is where most of the research points.

The anti-inflammatory effect holds up in vitro and in rodent colitis models, and the peptide's small size plus oral and topical absorption make it genuinely interesting pharmacologically. But the trail ends at preclinical. No published human RCT establishes benefit for inflammatory bowel disease, skin conditions, or recovery. The human case is plausible — and unproven. Those are not the same thing.

• Less colonic inflammation in animal models of colitis
• Anti-inflammatory action on immune and epithelial cells in vitro
• Wound-healing and antimicrobial activity in skin models
• Direct uptake by intestinal cells, which is what makes oral dosing plausible

• No published human RCTs — clinical benefit is unproven
• Long-term human safety unknown
• Research-use-only sourcing; purity and dose vary
• Mechanistic overlap with a hormone pathway whose systemic effects are not fully characterized for this fragment

Research compound. Sold "for research use only" — not approved for human consumption.

Goals studied: Gut healing, Skin anti-aging

What is KPV used for in research?

Mostly inflammation — particularly gut inflammation like colitis — and some skin and wound applications, all at the preclinical stage.

Can KPV be taken orally?

In animal studies it is absorbed by intestinal cells, which is part of its appeal, but there are no human trials establishing an effective or safe oral dose.

1. [1]
   PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

   Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D · Gastroenterology · 2008 · PMID 18061177 · model: animal

   Étude sur cellules et modèles murins de colite montrant que le KPV entre dans les cellules via PepT1 et atténue l'inflammation médiée par NF-κB.

2. [2]
   Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

   Kannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory Bowel Diseases · 2008 · PMID 18092346 · model: animal

   Étude sur modèles murins de MICI rapportant une réduction des lésions coliques et des cytokines inflammatoires sous KPV.